Other Events ·
Shareholders approve Cooperation Agreement with L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd
EVGNEvogene Ltd.
Evogene Ltd. shareholders approved a Cooperation Agreement with L.I.A. Pure Capital Ltd. and Invest-Pro Shukai Hon Ltd., effective as of the end of the special general meeting on November 10, 2026. The agreement resulted in a restructured board of directors comprising seven members: Nir Nimrodi, Leon Y. Recanati, Dr. Adi Zuluf-Shani, Oz Adler, Itai Maroz, Shahar Zadok, and Ofer Haviv, who remains President and CEO. Evogene Ltd. operates as a biotechnology company focused on artificial intelligence-driven drug discovery.